TrialEuropean journal of cancer (Oxford, England : 1990)2014

Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503).

J R Brahmer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.